LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Timeline
Attention over time
Attention Score history
Login
to access the full charts related to this output.
Activity
Login
to access the full charts related to this output.
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2024.
All research outputs
#1,903,670
of 34,306,620 outputs
Outputs from Annals of Oncology
#1,084
of 10,206 outputs
Outputs of similar age
#28,272
of 390,420 outputs
Outputs of similar age from Annals of Oncology
#30
of 254 outputs
Altmetric has tracked 34,306,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,206 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 390,420 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.
